« Back Nanomedicine: Nanotechnology, Biology and Medicine

Article in Press

Classification of lung cancer histology by gold nanoparticle sensors

  • Orna Barash, MSc

      Affiliations

    • The Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology, Haifa, Israel
    • These two authors contributed equally to this work.
    • ,
  • Nir Peled, MD, PhD

      Affiliations

    • University of Colorado Cancer Center, Division of Medical Oncology, University of Colorado–Denver, Aurora, Colorado, USA
    • The Lung Cancer Unit, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
    • These two authors contributed equally to this work.
    • ,
  • Ulrike Tisch, PhD

      Affiliations

    • The Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology, Haifa, Israel
    • ,
  • Paul A. Bunn Jr., MD

      Affiliations

    • University of Colorado Cancer Center, Division of Medical Oncology, University of Colorado–Denver, Aurora, Colorado, USA
    • ,
  • Fred R. Hirsch, MD, PhD

      Affiliations

    • University of Colorado Cancer Center, Division of Medical Oncology, University of Colorado–Denver, Aurora, Colorado, USA
    • ,
  • Hossam Haick, PhD

      Affiliations

    • The Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology, Haifa, Israel
    • Corresponding Author InformationCorresponding author: Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology, Haifa 32000, Israel.

Received 10 April 2011 ,Accepted 3 October 2011. Published online 26 October 2011 Corrected Proof

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 O.B., N.P., U.T., P.B., and H.H. have no conflict to declare related to the study. F.H is a member of the consultant/advisory boards of AstraZeneca, Roche, Lilly, Pfizer, Boehringer-Ingelheim, Merck Serono, Ventana-Roche, Glaxo Smith Kline, BMS/Imclone, and Syndax.

 The research leading to these results has received funding from the FP7-Health Program under the LCAOS (grant 258868; H.H. and N.P.) and FP7′s ERC grant under DIAG-CANCER (grant 256639; H.H.), the NIH/Lung SPORE (F.H., P.B.), and the International Association for the Study of Lung Cancer (N.P.).

 All authors designed the research; O.B. and N.P. performed the research; U.T., O.B., N.P., and H.H. analyzed data, and U.T. and H.H. wrote the article.

PII: S1549-9634(11)00374-1

doi: 10.1016/j.nano.2011.10.001

« Back Nanomedicine: Nanotechnology, Biology and Medicine

Article in Press

Article Tools

* Image Usage & Resolution